[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospitals Cleveland Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":664},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,43,76,102,130,164,198,225,258,279,302,322,346,373,402,427,455,483,504,527,550,574,592,619,641],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100354736","an-early-feasibility-study-of-the-rehab-system-100354736",false,"NCT03898804","An Early Feasibility Study of the ReHAB System","An Early Feasibility Study to Assess the Effects of the \"Reconnecting the Hand and Arm to the Brain (ReHAB)\" System","ReHAB","Inclusion Criteria:\n\n1. Age between 22 and 65 years of age.\n2. Tetraplegia due to a static identified disease process (spinal cord injury or stroke) that prevents functional activity of the upper extremity.\n3. Onset of tetraplegia at least 12 months prior to enrollment, with stability of weakness for at least 3 months.\n4. Must have sufficiently intact cortical motor structures and stable medical prognoses to be able to perform the BCI control tasks for at least one year. .\n5. Ability to speak understandably or, if unable to speak understandably, a reliable means of yes\u002Fno communication.\n6. Life expectancy greater than 13 months.\n7. Chronic care environment within a three-hour drive of the study site or the ability to temporarily relocate to a residence within a three-hour drive of the study site.\n8. Willingness to remain available (geographically stable) for at least 13 months after enrollment, including maintenance of the evaluation schedule, frequent visits to the Investigator's office, and visits of Sponsor personnel to the subject's chronic care environment.\n9. Willingness to allow videotape recordings to be made of the surgical procedure (for training purposes) and portions of the Feasibility Evaluations.\n10. A stable psychosocial support system.\n11. Scalp devoid of any lesions or skin breakdown precluding surgery.\n12. Ability to provide voluntarily informed consent in accordance with Site institutional policies and willingness to release of Personal Health Information from the date of the injury or disease onset through the completion of the clinical Study.\n13. Availability of caregivers capable of providing the necessary daily care of the subject's skin and electrode externalization sites.\n\nExclusion Criteria:\n\n1. Presence of an implanted stimulator such as a pacemaker, spinal cord stimulator, cochlear implant, deep brain stimulator, vagus nerve stimulator, or defibrillator. (Implanted intrathecal pumps for pain or spasticity, cough implants, or diaphragmatic pacers are not excluded.)\n2. Any active infection(s) or unexplained fever.\n3. Active cancer within the one year prior to enrollment (other than adequately treated basal or squamous cell skin cancer).\n4. Uncontrolled insulin-dependent diabetes mellitus.\n5. Hydrocephalus requiring diversion of cerebrospinal fluid.\n6. Autonomic dysreflexia within three months prior to enrollment that required urgent evaluation and pharmacologic intervention prescribed by a physician.\n7. Seizure within 3 months prior to enrollment.\n8. Any medical condition expected to require routine MRI imaging or subjects with contraindication(s) to MRI.\n9. History of osteomyelitis or skin disorder that causes excessive skin sloughing, lesions or breakdown of the scalp.\n10. Chronic use of medications such as sedatives that may significantly retard motor coordination and cognitive ability.\n11. Chronic use of anticoagulant medications. (Subjects receiving prophylactic anticoagulation solely for the prevention of deep venous thrombosis are not excluded, but must be able to have their prophylactic anticoagulation suspended temporarily for the surgical procedure and immediate post-operative period.)\n12. Chronic use of steroids or immunosuppressant therapy.\n13. Active treatment for another serious medical, neurological or psychiatric disease or disorder that could seriously affect the subject's ability to undergo surgical implantation of the electrodes or participate in the testing sessions.\n14. Pregnant, lactating, or of childbearing age and not using adequate birth control.\n15. Active consumption of more than 1 alcoholic beverage per day.\n16. Suicide attempt within 12 months prior to enrollment.\n17. History of myocardial infarction or unstable cardiac arrhythmia.\n18. Enrollment in any other investigational study that may interfere with the time commitments required of this study.\n19. Subjects who are immunocompromised.\n20. Subjects who require ongoing diathermy or ultrasound treatments.\n21. Subjects with severe upper extremity joint contractures or Ashworth spasticity scores of 4 that would limit functional movements.\n22. Subjects who have contraindication(s) to CT.\n23. Subjects who are ventilator dependent. Subjects who are sometimes ventilator-assisted (for example, while sleeping) are not excluded.","ALL","22 Years","65 Years",{"count":22,"type":23},12,"ESTIMATED","INTERVENTIONAL",[26],"NA","The purpose of this research study is to examine the feasibility of a system that involves implanting small electrodes in the parts of the brain that control movement and sensation, and combining that with electrodes in the upper arm and shoulder to activate paralyzed muscles of the arm and hand. This system is intended for people with extensive paralysis in their arms. The small electrodes in the brain will be used to attempt to measure intended movements, and the muscles in the arm and hand will be stimulated to attempt to follow those intentions.\n\nThe study is a prospective, non-randomized, open-label, exploratory safety\u002Ffeasibility trial of up to 12 subjects. The Primary Endpoint will be evaluation over the first 13 months after implantation, after which the subjects will have the option of removal of the device or continued participation in a long-term study.",[29],"Tetraplegia","RECRUITING","2026-08-18",{"date":33,"type":34},"2026-08-20","ACTUAL",{"date":36,"type":34},"2019-04-09",{"date":38,"type":23},"2029-08-01",{"name":40,"class":41},"University Hospitals Cleveland Medical Center","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":18,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100652121","non-nutritive-sweeteners-in-inflammatory-bowel-disease-100652121","NCT07769437","Non-nutritive Sweeteners in Inflammatory Bowel Disease","The Effect of Non-Nutritive Food Sweeteners in Inflammatory Bowel Disease","Inclusion Criteria:\n\nAge range from: 18 to 70 years. Male or female. Documented diagnosis of Crohns disease. CD outpatients in remission; Harvey Bradshaw- index in remission (\\\u003C6 score).\n\nCapable of providing consent to participate. Able to complete daily surveys and take oral nutrition. Able to record meal intake. Healthy controls with no diagnosis of IBD or Irritable Bowel Syndrome (IBS).\n\nExclusion Criteria:\n\nShort bowel syndrome. Hospitalized patients. Individuals who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, dementia patients.\n\nKnown drug abuse. Known parasitic disease of the digestive system. Symptomatic intestinal stricture\u002Fnarrowing. Presence of an ostomy. Known active malignancy. Antibiotic use within last 14 days. Well-founded doubt about the patients cooperation. Existing pregnancy or lactation. History of \\\u003C1 natural bowel movements per 3 consecutive days. Unable to access to technology that permits the daily completion of study related activities.\n\nChange in IBD medication within past 4 weeks. Body mass Index \\\u003C18 kg\u002Fm or ≥35 kg\u002Fm. Documented C.difficile colitis within four weeks of screening. Bariatric surgery Phenylketonuria",true,"18 Years","70 Years",{"count":54,"type":23},40,[26],"This study will focus on the commonly used non-nutritive sweetener (NNS) sucralose (2 sachets\u002Fday resulting in daily dose: sucralose 2.5mg\u002Fkg) and its role in changing the gut microbiota in humans with IBD, compared to healthy non-IBD individuals. We will focus on studying IBD patients affected with CD as a proof of principle that could be tested later in other IBD subtype (ulcerative colitis or others specific surgical conditions).",[58,59],"Inflamatory Bowel Disease","Crohn Disease (CD)",[61,62,63,64,65,66,67],"sweeteners","sucralose","inflammatory bowel disease","crohn's disease","IBD","CD","artificial sweeteners","2026-08-11",{"date":31,"type":34},{"date":71,"type":34},"2025-02-03",{"date":73,"type":23},"2026-12",{"name":40,"class":41},3,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":42},"100650906","pop-singer-randomized-clinical-trial-100650906","NCT07756541","POP SINGER Randomized Clinical Trial","Pain Management Optimized Through Patient-centered Multi-Session Group Music Therapy Within INteGrative sharEd progRamming: A Feasibility Randomized Controlled Trial","POP SINGER RCT","Inclusion Criteria:\n\n1. Adults aged 18 and older\n2. Reporting pain on most days per month for a duration of ≥3 months\n3. Independently ambulatory (i.e., able to walk 10 feet without a cane or walker)\n4. Willing to participate in the full scope of the program\n5. Access to internet, active email address, \\& laptop, tablet, and\u002For PC with videoconferencing capabilities\n6. Have reliable access to a mobile device with an active data plan at home and is comfortable accessing the internet and their email with this device\n7. Able to read and understand English\n\nExclusion Criteria:\n\n1. Significant hearing and\u002For visual impairment\n2. Have had a major surgery (e.g., spine surgery, joint replacement) within the past 6 months\n3. Have a planned surgery within the next 6 months at the time of enrollment\n4. Unable to independently provide consent (i.e., no proxy consent)\n5. Active suicidal ideation\n6. Severe psychological comorbidity (e.g., psychosis, schizophrenia) that would prevent patient from engaging fully in intervention\n7. Receiving active cancer treatment.\n8. Diagnosed with medical condition likely to be terminal within 24 weeks\n9. Either (a) active substance abuse of cocaine, heroin, cannabis, or alcohol or (b) unmanaged opioid use disorder diagnosis present within the EHR in the last 6 months\n10. Currently receiving music therapy from a professional music therapist\n11. Currently engaged in regular weekly yoga practice",{"count":85,"type":23},130,[26],"Conduct a feasibility randomized controlled trial (N = 130, 65 per group) comparing the POPSINGER music therapy (MT) intervention to yoga.",[89],"Chronic Pain",[91,92,93],"Chronic pain","Music Therapy","Yoga","2026-08-06",{"date":96,"type":34},"2026-08-10",{"date":98,"type":34},"2026-07-29",{"date":100,"type":23},"2028-08-01",{"name":40,"class":41},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":50,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":110,"targetDuration":112,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100649319","prospect-registry-for-individuals-at-risk-for-genetic-prion-disease-100649319","NCT07732608","PROSPECT Registry for Individuals at Risk for Genetic Prion Disease","PROSPECT: A Registry and Longitudinal Natural History Study of Individuals at Risk for Genetic Prion Disease","PROSPECT","Inclusion Criteria:\n\n* Age ≥18 years\n* At risk for genetic prion disease based on family history\n* Willing to comply with all study procedures including genetic testing and longitudinal follow-up\n* Resident in the United States\n* Sufficiently proficient in English to participate in all study procedures\n\nExclusion Criteria:\n\n* Lacking capacity to independently consent at time of initial enrollment\n* Symptomatic of prion disease at time of initial enrollment\n* Inability to provide a backup contact",{"count":111,"type":23},1000,"10 Years","OBSERVATIONAL","PROSPECT is a prospective observational registry and longitudinal natural history study of adults at risk for genetic prion disease.",[116],"Prion Diseases",[118,119,120],"PRNP mutation","Natural history","Genetic testing","NOT_YET_RECRUITING","2026-07-28",{"date":124,"type":34},"2026-07-30",{"date":126,"type":23},"2026-08-17",{"date":128,"type":23},"2036-08",{"name":40,"class":41},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":137,"minAge":51,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":141,"briefSummary":143,"conditions":144,"keywords":148,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":42},"100474443","phase-4-postpartum-vaginal-estrogen-for-breastfeeding-patients-100474443","NCT05457972","Postpartum Vaginal Estrogen for Breastfeeding Patients","Postpartum Vaginal Estrogen for Sexual Function in Breastfeeding Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 or older\n* Sexually active\n* Singleton, term (37 weeks 0 days) birth\n* Planning to breastfeed or pump during the study period\n* History of successful breastfeeding or pumping after a prior pregnancy\n* Between 6 weeks and 6 months postpartum (patients may be recruited at any time during the postpartum period, but the study period will not start until 6 weeks postpartum)\n* Ability to consent in English\n* Not meeting any exclusion criteria\n\nExclusion Criteria:\n\n* Preterm delivery\n* Perinatal mortality\n* History of difficulty breastfeeding\n* 3rd or 4th degree perineal laceration\n* Any contraindications to estrogen, including, but not limited to, breast cancer or a history of breast cancer, estrogen-dependent neoplasia, active deep vein thrombosis (DVT)\u002Fpulmonary embolism (PE) or a history of these conditions, active arterial thromboembolic disease (for example, stroke and MI) or a history of these conditions, known anaphylactic reaction, angioedema, or hypersensitivity to estrogen, hepatic impairment or disease, protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.","FEMALE","50 Years",{"count":140,"type":23},100,[142],"PHASE4","Sexual dysfunction is very common in the postpartum period and is more common in people who breastfeed or pump. This research study was designed to help determine whether postpartum patients who use vaginal estrogen cream while breastfeeding have improved sexual function compared to postpartum patients who do not.",[145,146,147],"Breastfeeding","Postpartum Sexual Dysfunction","Vaginal Atrophy",[149,150,151,152,153,154,155],"vaginal atrophy","postpartum","sexual dysfunction","dyspareunia","breastfeeding","pumping","vaginal dryness","2026-07-22",{"date":158,"type":34},"2026-07-23",{"date":160,"type":34},"2025-02-22",{"date":162,"type":23},"2026-12-31",{"name":40,"class":41},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":50,"sex":137,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":176,"conditions":177,"keywords":184,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":42},"100567808","ovarian-tissue-allo-transplantation-100567808","NCT06673004","Ovarian Tissue Allo-transplantation","Ovarian Tissue Allo-Transplantation in the Setting of Primary Ovarian Insufficiency Between Non-Genetically Identical Siblings With Use of Immunosuppression","Inclusion Criteria (Donor):\n\n* Must meet criteria for ovarian sufficiency: Menstruating; Premenopausal serum hormone (FSH, LH, estradiol, AMH) levels\n* Must be between the ages of 21-35 years old.\n* Must be genetic sister to recipient participant, which will be assessed by patient report.\n* Must have history of at least one healthy live birth.\n* Must have more than one ovary (i.e. must have both the left and right ovary).\n* Must be willing to undergo a donor transplant evaluation including serologies and nucleic acid testing (NAT, which is essentially rapid PCR) for infectious conditions.\n* Must have normal female karyotype (46,XX).\n* Must have negative testing for HIV type 1 and 2, Hepatitis B, Hepatitis C, syphilis, West Nile Virus, gonorrhea and chlamydia.\n* Must be willing to undergo general anesthesia, minimally invasive gynecologic surgery, and loss of unilateral ovary.\n* If patient is a smoker, 3 months cessation is required prior to enrollment and must pass a nicotine test.\n* Must be willing and able to sign informed consent and follow all outlined procedures and recommendations in the protocol.\n* Donors (with their marital partners, when applicable) must be willing to seek independent legal advice from attorneys with specific expertise in third-party reproduction to determine their legal rights and duties in entering into a donor reproductive tissue arrangements.\n\nInclusion Criteria (Recipient):\n\n* Must meet criteria for primary ovarian insufficiency: Amenorrheic x12 months; Serum hormone (FSH, LH, estradiol, AMH) levels consistent with menopause\n* Must be between the ages of 21-40 years old.\n* Must be in a committed relationship with a male partner.\n* Must be willing to attempt natural conception within 4 months following transplant.\n* Must be willing to undergo a pre-transplant evaluation.\n* Must be willing to undergo Maternal Fetal Medicine consultation and evaluation for safety of pregnancy, particularly patients at risk of complications in pregnancy (e.g. Turner syndrome patients).\n* Must be willing to undergo general anesthesia, minimally invasive gynecologic surgery, pregnancy with potential high risk complications, and surgery to remove the graft\n* Must be willing and able to receive potent immunosuppressive medications and must be able to follow standard infection prophylaxis protocols\n* Must have been offered and declined donor oocyte IVF as a first line treatment option\n* Must be willing to receive standard vaccinations such as influenza, Hepatitis B. If age and circumstances indicate, be willing to receive vaccines against pneumococcus, HPV and Hepatitis A.\n* If patient is a smoker, 3 months cessation is required prior to enrollment and must pass a nicotine test.\n* Must be willing and able to sign informed consent and follow all outlined procedures and recommendations in the protocol, including assent for monitoring neonatal outcomes for the first year after birth.\n* Intended parents (meaning, the recipient and partner) must be willing to seek independent legal advice from attorneys with specific expertise in third-party reproduction to determine their legal rights and duties in entering into a donor reproductive tissue arrangements.\n\nInclusion Criteria (Recipient Male Partner)\n\n* Must be age 18 years or older (and a combined age not greater than 110 years).\n* Must have a normal semen analysis.\n* Must be willing and able to sign informed consent.\n* Intended parents (meaning, the recipient and partner) must be willing to seek independent legal advice from attorneys with specific expertise in third-party reproduction to determine their legal rights and duties in entering into a donor reproductive tissue arrangements.\n\nExclusion Criteria (Donor) (to be verified by history and review of the medical chart by the study team)\n\n* History of hypertension, diabetes, or significant heart, liver, kidney or central nervous system disease.\n* Any medical diagnosis placing the subject at high risk of surgical complications based on the team's review of medical history.\n* Current smoker (smoking cessation must have occurred 3 months prior to enrollment).\n* History of prior malignancy except for cervical cancer in stage 1a or 1b after 3 years.\n* History of human immunodeficiency virus (HIV), mycobacteria, hepatitis C.\n* Hepatitis B infection (Hepatitis B risk is for those with HepB surface antigen and\u002For HBV DNA positive. Those that are HepB core antibody true-positive are at minimal risk of reactivation. Those with vaccine-induced HepB surface antibody are not at risk).\n* Presence of active documented systemic infection or recent systemic infection within the past three months: Positive for syphilis (T. pallidum), chlamydia (C. trachomatis) or gonorrhea (N. gonorrhea).\n* BMI greater than 35 kg\u002Fm2\n\nExclusion Criteria (Recipient)\n\n* History of hypertension, diabetes, or significant heart, liver, kidney or central nervous system disease. Serum creatinine level \\>1.0 mg\u002FdL.\n* Any medical diagnosis placing the subject at high risk of surgical complications based on the team's review of medical history.\n* Current smoker (smoking cessation must have occurred 3 months prior to enrollment).\n* Active HPV infection.\n* History of prior malignancy except for cervical cancer in stage 1a or 1b after 3 years.\n* History of human immunodeficiency virus (HIV), mycobacteria, hepatitis C.\n* Hepatitis B infection (Hepatitis B risk is for those with HepB surface antigen and\u002For HBV DNA positive. Those that are HepB core antibody true-positive are at minimal risk of reactivation. Those with vaccine-induced HepB surface antibody are not at risk).\n* Presence of active documented systemic infection or recent systemic infection within the past three months.\n* Significant mental illness or substance abuse.\n* BMI greater than 30 kg\u002Fm2\n* Prior organ transplant with rejection, infection, or graft thrombosis.\n\nExclusion Criteria (Recipient Male Partner )\n\n* Inability to complete regular intercourse.\n* History of incarceration.\n* Significant mental illness or substance abuse.","21 Years","40 Years",{"count":174,"type":23},10,[26],"Premature ovarian failure, also known as primary ovarian insufficiency (POI), or premature menopause, affects 1-2% of women under 40. The diagnosis is typically made based on high levels of follicle stimulating hormone (FSH) and absent or irregular menstrual periods. It leads to infertility and menopause-like effects (hot flashes and thin bones) due to low estrogen levels. POI can result from various factors such as genetic conditions, autoimmune diseases, or previous medical treatments like chemotherapy.\n\nTreatment of POI usually involves hormone replacement therapy and, if pregnancy is desired, assisted reproductive technologies such as in vitro fertilization (IVF) using an egg donor. However, IVF may not be an option for everyone due to personal, religious, ethical or financial reasons. Recent advances in medicine have identified ovarian tissue transplantation (OTT) as a potential solution. OTT involves transplanting either fresh or frozen ovarian tissue into the pelvic area, where it can begin functioning again. Studies in animals and humans have shown success in restoring hormonal function and even achieving pregnancies in some cases. Initial human trials of ovarian tissue transplants from another individual began with identical twins and have since expanded to include non-identical siblings with compatible tissue matches using immunosuppression. Success rates of OTT have been promising, with multiple live births reported between identical twins. Long-term studies indicate that transplanted tissue can remain functional for up to eight years. Ovarian tissue transplantation offers a promising avenue for women with POI to help restore fertility and hormonal function. Continued research and refinement of tissue techniques are essential to improve outcomes and expand access to this innovative treatment option.\n\nThis study will enroll 10 participants who will undergo ovarian tissue transplantation donated by a non-identical sister using an immunosuppression protocol at University Hospitals.",[178,179,180,181,182,183],"Ovarian Failure","Ovarian Insufficiency","Menopause Ovarian Failure","Menopause, Premature","Infertility, Female","Endocrine Female Infertility",[185,186,187,188,189,190],"Primary ovarian insufficiency","Ovarian tissue transplantation","Immunosuppression","Premature menopause","Ovarian failure","Ovary transplant","2026-07-21",{"date":158,"type":34},{"date":194,"type":23},"2026-09-01",{"date":196,"type":23},"2030-05-30",{"name":40,"class":41},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":206,"enrollmentInfo":207,"targetDuration":209,"studyType":113,"phases":4,"briefSummary":210,"conditions":211,"keywords":215,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":42},"100622145","rectus-abdominis-detrusor-myoplasty-for-urinary-retention-100622145","NCT07379814","Rectus Abdominis Detrusor Myoplasty for Urinary Retention","To Investigate the Outcomes of Rectus Abdominis Flap Detrusor Myoplasty for Urinary Retention","RADM","Inclusion Criteria:\n\n* Hypo- or acontractility of the bladder documented on urodynamic testing\n* Injury \\>1 year ago for spinal cord injury patients, no improvement in contractility with time\n* Failed sacral nerve stimulation implant for urinary retention treatment (If previously implanted)\n* Irreversible non-neurogenic bladder acontractility\u002Fhypocontractility (i.e myogenic failure after chronic obstruction, aging, frailty, idiopathic)\n* Undergoing RADM\n\nExclusion Criteria:\n\n* Documented bladder outlet obstruction\n* Spinal cord lesion above T12\n* Upper motor neuron lesion (i.e. multiple sclerosis, stroke)\n* Rectus diastasis, significant abdominal wall hernia, or other anatomic barrier to rectus flap harvest\n* Life expectancy \\\u003C10 years\n* Pregnant at time of surgery","75 Years",{"count":208,"type":23},50,"1 Year","This investigates the outcomes of a surgical technique using the patient's own abdominal wall muscles to help contract the bladder in patients with urinary retention",[212,213,214],"Urinary Retention","Urinary Retention After Procedure","Urinary Retention Postoperative",[216],"urinary retention","2026-07-02",{"date":219,"type":34},"2026-07-06",{"date":221,"type":34},"2026-05-01",{"date":223,"type":23},"2036-05-01",{"name":40,"class":41},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":24,"phases":235,"briefSummary":236,"conditions":237,"keywords":241,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":42},"100592728","phase-4-deutetrabenazine-treatment-for-tardive-dyskinesia-in-intellectualdevelopmental-disabilities-100592728","NCT06997198","Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual\u002FDevelopmental Disabilities","Identification, Assessment, and Treatment of Tardive Dyskinesia With Deutetrabenazine in Adults With Intellectual\u002FDevelopmental Disabilities and Co-occurring Psychiatric and\u002For Behavioral Disorders","TD-AIDD","Participant Inclusion Criteria:\n\n* Diagnosis of IDD (IQ \\\u003C 70; social\u002Fadaptive dysfunction, onset \\\u003C age 22) as per DSM-5\n* Clinical diagnosis of Tardive Dyskinesia (TD) per DSM-5 for at least 3 months before study inclusion (presence of movement disorder for at least 3 months, in absence of previous formal diagnosis of TD).\n* Eligible to receive deutetrabenazine, according to current product labeling Stable doses of all psychotropic medications for minimum of three months before study inclusion\n* Willing to remain on stable doses of all psychotropics for 24 weeks of study. If female of childbearing age, practicing acceptable form of birth control throughout study duration.\n* Subject able to comply with scheduled visits and assessments\n* Consent of subject, or legally authorized representative to study protocol.\n\nCaregiver Inclusion Criteria:\n\n* Able to understand and answer questionnaires\n* Able to comply with scheduled visits\n* Ability to be primary Caregiver for 24 weeks of study\n\nParticipant Exclusion Criteria:\n\n* Previous treatment with a VMAT2 inhibitor (tetrabenazine, valbenazine, or deutetrabenazine).\n* Treatment with any investigational drug in the 30 days prior to study entry.\n* Currently taking a strong CYP2D6 inhibitor such as fluoxetine, paroxetine, quinidine, bupropion. Current treatment with strong anticholinergic agents, monoamine oxidase inhibitors, metoclopramide, dopamine agonists, L-DOPA, or stimulants within past 30 days, or botulinum toxin within the past 3 months.\n* Any unstable medical condition in the 60 days prior to study entry.\n* Pregnant or breast-feeding\n* Current or recent hepatic impairment\n* History of neuroleptic malignant syndrome\n* History of long QTc on electrocardiogram, bundle branch block (BBB), atrioventricular block, serious cardiac arrhythmia, or heart failure.\n\nQTc on EKG \\> 450 msec (Fredericia formula) on EKG within 3 months prior to study entry.\n\n* History of substance abuse or dependence in the 3 months prior to study entry.\n* Significant risk of suicide or dangerous aggression to others at time of or 3 months prior to study entry.\n* Inability to take study medications\n\nCaregiver Exclusion Criteria:\n\n* Unable to complete questionnaires\n* Unable to comply with scheduled visits\n* Will not be a primary Caregiver for the 24 weeks of the study","89 Years",{"count":7,"type":23},[142],"The primary goal of this study is to investigate the efficacy of deutetrabenazine treatment of TD in this previously untreated patient population. Compare movement disorder deutetrabenazine treatment response in persons with IDD to response seen in patients without IDD treated with deutetrabenazine in other treatment settings (per literature review). Compare global deutetrabenazine treatment response with validated instruments.\n\nIn addition, we plan to:\n\n* Assess the safety of deutetrabenazine in the treatment of TD in persons with IDD.\n* Assess change in Activities of Daily Living (ADLs) in persons with IDD and TD treated with deutetrabenazine, utilizing a validated ADL instrument.\n* Assess change in Quality of Life (QOL) in persons with IDD and TD treated with deutetrabenazine, utilizing a validated QOL instrument.\n* Assess caregiver burden with a validated caregiver burden instrument.\n\nIn this study, 25 participants with IDD and TD will undergo Deutetrabenazine treatment for 24 weeks. The participants will be seen for a total of 5 visits: at baseline, and at follow up visits at 3 weeks, 6 weeks, 12 weeks, and 24 weeks.\n\nThis study does not include a comparison group. Therefore, researchers will compare the response of the study participants to deutetrabenazine treatment with those from a previous reported work that resulted in the FDA approval of this medication. This will be an open-label, Phase 4 study.",[238,239,240],"Tardive Dyskinesia","Intellectual Disability","Developmental Disabilities",[242,243,244,245,246,247,248,249,250],"movement disorders","antipsychotic medication adverse effects","Abnormal Involuntary Movement Scale","quality of life","adaptive behavior","caregiver burden","deutetrabenazine","selective vesicular monoamine transporter 2 inhibitor","VMAT2 inhibitor","2026-07-01",{"date":219,"type":34},{"date":254,"type":34},"2026-06-22",{"date":256,"type":23},"2027-10-01",{"name":40,"class":41},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":137,"minAge":51,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":24,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":42},"100591107","application-of-a-prediction-model-for-directing-antibiotic-use-in-the-treatment-of-urinary-tract-infection-in-an-ambulatory-setting-100591107","NCT06976125","Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting","Inclusion Criteria:\n\n* Female sex\n* Age \\>18 years old\n* Discharged from the hospital after ER visit\n* Discharge ICD code consistent with a UTI diagnosis\n* Antibiotic prescribed for UTI at the time of discharge\n\nExclusion Criteria:\n\n* Male sex\n* Necessity for chronic bladder catheterization or discharge with a urinary catheter\n* Patients who have an Emergency Severity Index (ESI) of 1 and 2\n* Patients who verbalize to the study team member that their pain is a 6 or higher\n* Patient set to be transferred to inpatient care\n* History of bladder augmentation\n* Pregnancy (this will be confirmed with a negative pregnancy test which is ordered in the ER)",{"count":265,"type":23},47,[26],"Urinary tract infection (UTI) is when bacteria enter the urinary system and cause an infection. UTIs cause symptoms including burning when peeing, a feeling of an increased urge to pee, and cloudy or strong-smelling urine. Sometimes, severe UTIs can also cause fever, abdominal pain, and\u002For lower back pain.\n\nIn the emergency department (ED), healthcare providers rely on symptoms, along with a urine analysis and a urine culture to diagnose a UTI. A urine analysis involves taking a sample of urine and analyzing different factors like color, acidity, presence of blood cells, presence of bacteria. An abnormal urine analysis increases the likelihood that patients might have a UTI, but it does not confirm it. A positive urine analysis will lead to provider's sending a sample of urine for a urine culture. A urine culture is used to grow whatever bacteria is in the collected urine. If growth is seen on the culture, then this confirms a patient has a UTI. This also specifies which bacteria grew on the culture. The lab can also take it a step further and do an antibiotic test to check which antibiotic the bacteria is sensitive to.\n\nWhen a urine analysis comes back abnormal in an ER setting, patients are prescribed an antibiotic before the culture and antibiotic sensitivity tests come back. If a patients condition is not critical, they will be discharged home before the culture results come back. If the culture comes back positive, the pharmacists will evaluate the culture and antibiotic sensitivity tests, then call patients to inform them whether they are taking a suitable antibiotic.\n\nThis study aims to decrease the unnecessary use of antibiotics because this contributes to antibiotic resistance which is considered a global public health issue. Antibiotic resistance occurs when bacteria develop the ability to withstand certain antibiotics that used to be effective against them, which makes it difficult to treat the infection. One of the factors that increase the risk of antibiotic resistance is the overuse of antibiotics.\n\nIn this study, investigators will be incorporating a prediction model and a negative callback system to decrease unnecessary antibiotic use.",[269],"Urinary Tract Infections",[271,272],"ER visits","Antibiotic use",{"date":219,"type":34},{"date":275,"type":34},"2026-02-20",{"date":277,"type":23},"2026-12-15",{"name":40,"class":41},{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":233,"enrollmentInfo":285,"targetDuration":4,"studyType":24,"phases":287,"briefSummary":288,"conditions":289,"keywords":293,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":42},"100572454","innovating-physical-therapy-a-pilot-study-on-band-connects-impact-on-compliance-satisfaction-and-revenue-100572454","NCT06733480","Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue","Inclusion Criteria:\n\n* Age range: from 18 to 89 years old\n* Surgery performed by Dr. Robert Gillespie and will be undergoing post-op physical therapy rehabilitation at University Hospitals\n* Patients undergoing primary anatomic total shoulder shoulder arthroplasty (aTSA) or primary reverse total shoulder arthroplasty (rTSA)\n* Patients undergoing primary rotator cuff repair\n* Prescribed outpatient physical therapy for post-operative rehabilitation\n\nChart Review Inclusion Criteria:\n\n* Age range: from 18 to 89 years old\n* Surgery performed by Dr. Robert Gillespie who underwent post-op physical therapy rehabilitation at University Hospitals\n* Patients who underwent primary anatomic total shoulder shoulder arthroplasty (aTSA) or primary reverse total shoulder arthroplasty (rTSA)\n* Patients who underwent primary rotator cuff repair\n* Prescribed outpatient physical therapy for post-operative rehabilitation\n\nExclusion Criteria:\n\n* Patients undergoing hemiarthroplasty or revision TSA\n* Patients undergoing revision rotator cuff repair\n* TSA performed for proximal humerus fractures\n* Length of stay in hospital following shoulder surgery greater than 3 days\n* Shoulder injuries related to workers compensation or involved in any pending litigation\n* Pregnant individuals\n\nChart Review Exclusion Criteria:\n\n* Patients undergoing hemiarthroplasty or revision TSA\n* Patients undergoing revision rotator cuff repair\n* TSA performed for proximal humerus fractures\n* Length of stay in hospital following shoulder surgery greater than 3 days\n* Shoulder injuries related to workers compensation or involved in any pending litigation\n* Pregnant individuals",{"count":286,"type":23},499,[26],"Participants are being invited to take part in this research study because you will be undergoing total shoulder replacement or rotator cuff repair and will be participating in physical therapy rehabilitation following the procedure. The purpose of this research is to investigate the effectiveness of Band Connect, a connected health platform, in enhancing compliance with home exercise programs among patients undergoing physical therapy. This study aims to evaluate the implications of increased compliance on improving patient engagement and increasing satisfaction for both patients and clinicians. Additionally, the study will analyze the economic implications of implementing Band Connect's hybrid care model on driving increased revenue per patient.",[290,291,292],"Rotator Cuff Tears","Anatomic Total Shoulder Arthroplasty","Reverse Total Shoulder Arthroplasty",[294,295],"physical therapy compliance","home-based physical therapy",{"date":219,"type":34},{"date":298,"type":34},"2025-02-04",{"date":300,"type":23},"2027-06-01",{"name":40,"class":41},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":309,"enrollmentInfo":310,"targetDuration":209,"studyType":113,"phases":4,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":75},"100557901","use-of-thermal-imaging-camera-to-assess-perfusion-before-and-after-vascular-intervention-100557901","NCT06544135","Use of Thermal Imaging Camera to Assess Perfusion Before and After Vascular Intervention","TIC","Inclusion Criteria:\n\n* Lower extremity peripheral artery disease with tissue loss consistent with Rutherford classification V or VI.\n* Planned lower extremity endovascular intervention\n\nExclusion Criteria:\n\n* Non-arterial ulcers\n* Pregnant","99 Years",{"count":7,"type":23},"This is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure.\n\nThe main question this study aims to answer is:\n\n\\- Are temperature measurements from a forward looking infrared (FLIR) camera of the lower extremity useful in predicting outcome of revascularization procedures?",[313,314,315],"Peripheral Arterial Disease","Critical Limb Ischemia","Critical Lower Limb Ischemia",{"date":217,"type":34},{"date":318,"type":34},"2025-04-14",{"date":320,"type":23},"2027-10",{"name":40,"class":41},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":233,"enrollmentInfo":329,"targetDuration":4,"studyType":24,"phases":331,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":75},"100631212","phase-4-omt-for-adhesive-capsulitis-100631212","NCT07497737","OMT for Adhesive Capsulitis","Osteopathic Manipulative Treatment as an Adjunct Therapy for Adhesive Capsulitis","Inclusion Criteria:\n\n* patients diagnosed with adhesive capsulitis who have not received prior treatment for it\n\nExclusion Criteria:\n\n* patients with contraindications to corticosteroid injections (uncontrolled diabetes, active infection, bleeding disorders, or corticosteroid hypersensitivity)\n* patients diagnosed with adhesive capsulitis who have received (or are currently receiving) treatment for it",{"count":330,"type":23},300,[142],"The goal of this clinical trial is to learn if Osteopathic Manipulative Treatment (OMT) is an effective addition to treatment of adhesive capsulitis. OMT is a non-invasive treatment in which a doctor gently moves and stretches muscles, joints, and tissues manually. Adhesive capsulitis is more commonly known as \"frozen shoulder\" and describes a shoulder that becomes stiff, painful, and limited in its motion due to some structural change in the joint. The main questions it aims to answer are:\n\nIs recovery faster when OMT is added to regular treatment? Are patients that underwent OMT more satisfied with their treatment?\n\nResearchers will compare patients who underwent OMT to patients who did not to see if OMT is an effective additional treatment for frozen shoulder.\n\nParticipants will:\n\n* Be assigned to one of the four experimental groups\n* Visit clinic and\u002For physical therapy to undergo the treatments associated with their group:\n\n  1. standard course of prescribed physical therapy\n  2. standard course of prescribed physical therapy and an injection of an anti-inflammatory and anesthetics in the shoulder\n  3. standard course of prescribed physical therapy and (up to) 4 OMT sessions\n  4. standard course of prescribed physical therapy, an injection of an anti-inflammatory and anesthetics in the shoulder, and (up to) 4 OMT sessions.\n* Visit clinic 1 month, 3 months, 6 months, and 1 year after treatment is complete\n* Complete a survey about how satisfied they are with their treatment 1 month, 3 months, 6 months, and 1 year after it is complete",[334,335],"Adhesive Capsulitis of the Shoulder","Frozen Shoulder",[337,334,335],"Osteopathic Manipulative Treatment (OMT)","2026-06-08",{"date":340,"type":34},"2026-06-09",{"date":342,"type":23},"2026-08-01",{"date":344,"type":23},"2028-05-01",{"name":40,"class":41},{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":24,"phases":355,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":372,"locationsCount":42},"100546782","mediterranean-diet-vs-no-dietary-intervention-for-improving-signs-and-symptoms-of-psoriasis-in-patients-treated-with-anti-il-17-or-anti-il-23-inhibitors-100546782","NCT06399432","Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors","Inclusion Criteria:\n\n* Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening.\n* Have moderate to severe plaque psoriasis at Baseline as defined by\n\n  1. BSA ≥5% OR\n  2. sPGA ≥3 (moderate to severe) OR\n  3. PASI ≥5\n* Must have been prescribed, per standard-of-care, an Anti-IL-17 or Anti-IL-23 therapy for psoriasis, which the patient has not yet started, but is willing to start during the study.\n\nEligible therapies are Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab, and Tildrakizumab.\n\n* Must be in good health (except for psoriasis) as judged by the Investigator, based on medical history and physical examination.\n* Must be eligible for a weight loss program, defined as being in good general health and having a BMI between 25 to 40.\n\nExclusion Criteria:\n\n* Other than psoriasis, history of any clinically significant (as determined by the Investigator) cardiac (clinically advanced cardiovascular disease including stent, past history of MI, thrombotic event or arterial calcification), active or history of inflammatory bowel disease, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease.\n* Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he\u002Fshe were to participate in the study.\n* Any condition, including other inflammatory diseases or dermatologic conditions that confound the ability to interpret data from the study.\n* Prior history of suicide attempt at any time in the subject's lifetime prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.\n* Pregnant or breast-feeding.\n* Have failed more than 3 systemic agents for treatment of psoriasis.\n* History of allergy to any component of Anti-IL-17 or Anti-IL-23 therapies.\n* Had a serious infection (including, but not limited to, hepatitis, pneumonia, sepsis, cellulitis, meningitis or pyelonephritis) or have been hospitalized for an infection. Subject must be cured of infection \\> 4 weeks before Screening.\n* Have a history of, or ongoing, chronic or recurrent infectious disease, including, but not limited to, chronic renal infection, chronic chest infection (e.g., bronchiectasis), sinusitis, recurrent urinary tract infection (e.g., recurrent pyelonephritis, chronic non-remitting cystitis), an open, draining, or infected skin wound or ulcer.\n* Had a Bacillus Calmette-Guérin (BCG) vaccination within 1 year prior to screening.\n* History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency (e.g., common variable immunodeficiency disease).\n* Active substance abuse or a history of substance abuse within 6 months prior to Screening.\n* Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment and cure for such infections must have been completed at least 4 weeks prior to Screening.\n* Malignancy or history of malignancy, except for:\n\n  1. treated \\[i.e., cured\\] basal cell or squamous cell in situ skin carcinomas;\n  2. treated \\[i.e., cured\\] cervical intraepithelial neoplasia \\[CIN\\] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years.\n* Have a known nut allergy.\n* Currently participating in a supervised dietary program.\n* Use of psoriasis therapy 2 weeks prior to Baseline (including, but not limited to, topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, anthralin\u002Fdithranol, cyclosporine, corticosteroids, methotrexate, retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine, fumaric acid esters, TNF inhibitors IL-17 inhibitors, IL-12\u002F23 inhibitors, or phototherapy).\n\nExceptions: Low-potency corticosteroids will be allowed as background therapy and restricted to treatment of the face, axillae, and groin in accordance with the manufacturers' suggested usage during the course of the study (this restricted usage should be documented). Subjects with scalp psoriasis will be permitted to use coal tar shampoo and\u002For salicylic acid scalp preparations on scalp lesions. An unmedicated skin moisturizer (e.g. Eucerin®) will be also permitted for body lesions only. Subjects should not use these topical treatments within 24 hours prior to the clinic visit.\n\n* Use of any investigational drug within 2 weeks prior to Baseline.\n* Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources.\n* Currently flaring or unstable psoriasis.","94 Years",{"count":354,"type":23},36,[26],"In this study, participants will have 3 or 4 total study visits over approximately 10 total weeks. There is a two week medication washout period in between the 1st and 2nd visits. This washout only applies if participants are using a prohibited psoriasis medication (such as topical steroids or oral psoriasis medications, like methotrexate). During the washout period, participants will have to stop the prohibited medication(s). If participants are not using any prohibited medications, then the 1st and 2nd visits can be combined and participants will only have 3 total in-person visits. Participants will be randomly assigned (by chance; like flipping a coin) to either the Mediterranean Diet or no dietary intervention. After 4 weeks on the diet, participants will start treatment with either Anti-IL-17 or Anti-IL-23 therapy. The biologic treatments will prescribed by the participants regular dermatologist and not as a part of the study.",[358],"Psoriasis",[360,361,362,363,364,365],"risankizumab","tildrakizumab","brodalumab","izekizumab","secukinumab","guselkumab","2026-06-02",{"date":368,"type":34},"2026-06-03",{"date":370,"type":34},"2022-10-18",{"date":251,"type":23},{"name":40,"class":41},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":137,"minAge":51,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":24,"phases":383,"briefSummary":384,"conditions":385,"keywords":388,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":42},"100574035","believe-trial-bulking-versus-sling-for-treating-stress-urinary-incontinence-at-the-time-of-vaginal-prolapse-repair-believe-100574035","NCT06754046","BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)","BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair","BELIEVE","Inclusion Criteria:\n\n* Women ≥ 18 years of age.\n* Have diagnosis of symptomatic or occult stress urinary incontinence (SUI) as noted in their electronic health record (EHR).\n* Proof of positive testing for SUI via cough stress test (CST) and\u002For Urodynamic (UDS) testing,\n* Patients that are planning and eligible for native tissue prolapse repair and for both Retropubic Midurethral Sling (RP-MUS) and Polyacrylamide Hydrogel (PAHG)\n\nExclusion Criteria:\n\n* Patients undergoing pelvic organ prolapse repair using mesh or biologic augmentation other than patient's own tissue\n* Patient anticipating difficulty with completing 24-month follow-up\n* Anticipation of pregnancy within subsequent 24-months or \\\u003C18 months post-partum\n* Hemoglobin A1c \\>10.0% within the past 3-months\n* Current smoker \\> 1 pack per week\n* History of neurogenic bladder\n* Current use of any catheterization including but not limited to, intermittent catheterization, indwelling Foley catheter, or suprapubic catheter\n* Post-void residual \\>150 mL felt to not be due to obstruction for prolapse\n* Prior history of any anti-incontinence procedure including but not limited to any synthetic sling, fascial sling, Burch colposuspension or its variants, and urethral bulking\n* Previous history of any pelvic radiation\n* Patient receiving a planned concurrent procedure at the time of prolapse repair.",{"count":382,"type":23},476,[26],"The goal of this clinical trial is to learn if retropubic midurethral sling (RP-MUS) or bulkamide injection (PAHG) at the time of pelvic organ prolapse repair is better from the patient's perspective. The main questions it aims to answer are:\n\nWhat is the average difference in the urogenital distress inventory (UDI) long form score 24 months after surgery for each procedure? Which procedure has the fewest complications and lowest short- and long-term morbidity profile?\n\nParticipants will:\n\nBe blinded and randomized to one of two procedures for the duration of the study, 24 months.\n\nComplete 6 total visits for the clinical trial including validated questionnaires.\n\nFew participants will be selected to complete a qualitative interview at 3 timepoints over 24 month duration of the study.",[386,387],"Stress Urinary Incontinence","Vaginal Prolapse",[389,390,391,392,393],"midurethral sling","bulkamide","polyacrylamide hydrogel","urethral bulking","retropubic sling","2026-05-27",{"date":396,"type":34},"2026-06-01",{"date":398,"type":34},"2025-05-01",{"date":400,"type":23},"2029-04",{"name":40,"class":41},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":24,"phases":411,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":426},"100637818","surgical-ergonomics-in-obgyn-100637818","NCT07609420","Surgical Ergonomics in OBGYN","Surgical Ergonomics in OBGYN Trainees & Attendings","Inclusion Criteria:\n\nCurrent attending in the OBGYN department at University Hospitals Current resident or fellow in the OBGYN department at University Hospitals Participation in laparoscopic or open surgical procedures\n\nExclusion Criteria:\n\nNot a current fellow, resident, or attending in the OBGYN department at University Hospitals","90 Years",{"count":208,"type":23},[26],"This is a voluntary research study to implement and assess the efficacy of interventions aimed to improve surgical ergonomics in OBGYN residents, fellows, and attendings and decrease the incidence of work-related musculoskeletal disorders (WRMD). We want to learn the baseline incidence of WMRD in our population and to see if the implementation of a surgical ergonomics lecture, pre-operative surgical ergonomics time-out, and intra-operative stretch breaks will improve the incidence of WRMD in this population.",[414],"Current OBGYN Attending, Resident, or Fellow at University Hospitals",[416,417,418],"surgical ergonomics","obstetrics & gynecology","medical education","2026-05-19",{"date":394,"type":34},{"date":422,"type":23},"2026-08-12",{"date":424,"type":23},"2027-07-16",{"name":40,"class":41},2,{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":434,"maxAge":435,"enrollmentInfo":436,"targetDuration":4,"studyType":24,"phases":437,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":42},"100633842","phase-1-escalating-doses-of-memantine-in-down-syndrome-meds-123-100633842","NCT07531940","Escalating Doses of Memantine in Down Syndrome (MEDS-123)","Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome","Inclusion Criteria:\n\n* Cytogenetically documented Trisomy 21 or Complete Unbalanced Translocation of Chromosome 21. Mosaic Trisomy 21 and partial translocations will be excluded from the study\n* No pregnancy by serum testing at screening. Females of child-bearing potential, sexually active must be practicing a reliable method of birth control. Urine pregnancy tests will be done at the 2 follow-up medical visits\n* Laboratory findings within normal limits or judged clinically insignificant at baseline\n* Vital signs within normal limits for age. Stable, medically treated hypotension will be allowed\n* ECG must demonstrate predominately normal sinus rhythm. Minor abnormalities documented as clinically insignificant will be allowed\n* Participants and their authorized representatives will provide written informed consent\n* Participants who have received any experimental drug for Down syndrome must undergo a washout\n* All participants must: Be in general good health as judged by the investigators; Be able to swallow oral medication; Have a reliable caregiver or family member who agrees to accompany participant to all visits, provide information about the participant as required by the protocol, and ensure compliance with the medication schedule; Be sufficiently proficient in English to reliably complete the study assessments\n* Age and gender matching participants without Down syndrome, must be: Males or females without Down syndrome aged-matching (within 3 years) participants with Down syndrome whom they are expected to serve as controls\n\nExclusion Criteria:\n\n* Participant weighing less than 40 kg\n* Current psychiatric or neurologic diagnosis other than Down syndrome (e.g., major depressive disorder, schizophrenia, bipolar disorder, autism, Alzheimer disease)\n* Current treatment with psychotropic drugs\n* Drug or alcohol abuse or dependence\n* Significant suicide risk or who would require treatment with electro-convulsive therapy or with psychotropic drugs during the study or who have received treatment with a depot neuroleptic drug within 6 months of entering the study.\n* Current or expected (within the next 6 months) hospitalization or residence in a skilled nursing facility (may reside in group homes or other residential settings with no skilled nursing)\n* Active or clinically significant conditions affecting absorption, distribution, or metabolism of study drug (e.g. inflammatory bowel disease or celiac disease)\n* Significant allergies to or other significant intolerance of memantine therapy, its ingredients, or with contraindications to memantine therapy as stated in the prescribing information\n* Participants who are expected to require general anesthetics during the course of the study\n* Presence or recent history of seizure disorder (\\\u003C 3 years).\n* Clinically significant and\u002For clinically unstable systemic disease. (Those with controlled hypothyroidism must be on a stable dose of medication for at least 3 months prior to screening and have normal serum T-4 and TSH at screening; and those with controlled diabetes mellitus must have an HbA1c of \\\u003C 8.0% and a random serum glucose value of \\\u003C 170 mg\u002Fdl)\n* Severe infections or a major surgical operation within 3 months prior to screening\n* History of persistent cognitive deficits immediately following head trauma.\n* Donation of blood or blood products less that 30 days prior to screening, while participating in the study, or four weeks after completion of the study\n* Inability to comply with the protocol or perform the outcomes measures due to significant hearing or visual impairment or other issues judged relevant by the investigators","15 Years","32 Years",{"count":7,"type":23},[438],"PHASE1","Down syndrome (DS) is typically caused by an extra chromosome 21 in the cell nucleus (trisomy 21, or T21). T21 is both the most common cause of genetically defined intellectual disability and the earliest documented cause of Alzheimer's disease (AD)-type pathology. Currently, all presymptomatic individuals with DS are classified as having 'Stage 0' DS-associated AD (DSAD). DSAD pathology evolves inexorably, with virtually all individuals with DS developing AD pathology by age 40, and approximately 50% meeting clinical dementia diagnosis criteria at 55 years of age. This study will test the hypothesis that the FDA-approved AD drug memantine, at higher-than-standard doses, may be effective as a cognitive enhancer in adolescents and young adults with DS. The primary goal of this phase 1b clinical trial will be the assessment of the safety and tolerability of three memantine doses in persons with DS. In addition, we will assess the effect of this drug on cognitive test scores and plasma biomarkers of AD in the study participants. Finally, we will also investigate steady-state plasma levels of memantine and the time course of memantine plasma levels after a single dose in the study participants (pharmacokinetics, or PK). The data generated through this phase 1b study will provide the essential safety, PK, and preliminary efficacy signals required to advance a phase 2 trial evaluating high-dose memantine as a first-in-class therapeutic strategy in DS.",[441,239],"Down Syndrome",[443,444,445,446],"Memantine","Episodic Memory","CVLT","Short-term memory","2026-05-05",{"date":449,"type":34},"2026-05-11",{"date":451,"type":23},"2026-06",{"date":453,"type":23},"2028-05",{"name":40,"class":41},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":233,"enrollmentInfo":462,"targetDuration":4,"studyType":24,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":42},"100566823","sternal-plating-high-risk-100566823","NCT06660186","Sternal Plating High Risk","Randomized Trial of Rigid Plate Fixation Versus Wire Cerclage in High-Risk Sternotomy Patients","Preoperative Inclusion Criteria\n\n* Adults (age range: 18-89)\n* Undergoing cardiac surgery through sternotomy\n\n  -≥2 risk factors:\n* Diabetes mellitus\n* Severe COPD\n* Chronic steroid use\n* Immunosuppression\n* Redo sternotomy\n* Chronic\n* Kidney disease with GFR \\>30 ml\u002Fmin per 1.73m2\n* Radiation therapy\n* BMI≥35\n* High-risk of delirium\n* Heavy alcohol use\n\nPreoperative Exclusion Criteria\n\n* Active malignancy\n* Chronic narcotic use\n* NYHA Class IV\n* Known nickel metal allergy\n* Compliance concern\n* eGFR\\\u003C30 ml\u002Fmin per 1.73m2\n* Involvement in another interventional clinical trial (non-registry)\n* Any criteria precluding RPF or WC\n\nOperative Inclusion Criteria\n\n* Off-midline sternotomy\n* BITA grafting\n* CPB time ≥120 minutes\n* Transverse sternal fracture\n\nOperative Exclusion Criteria\n\n* Emergent or emergent salvage surgery\n* Non-standard sternotomies\n* Sternotomy with bony margin \\\u003C2 mm\n* Bleeding\n* Delayed sternal closure\n* Surgical complications\n* Any criteria precluding RPF or WC",{"count":463,"type":23},250,[26],"Participants are being invited to participate in a research study at University Hospitals because they have heart disease and are scheduled for open heart surgery. Currently, UH cardiac surgeons close the sternum (or breastbone) after a sternotomy (procedure that allows a doctor to reach the heart and blood vessels) with either a rigid plate fixation Sternal Plate or a Wire Cerclage. However, the study team would like to further evaluate these two techniques. Any volunteer over the age of 18 who is at an increased risk for developing sternal wound complications may be eligible to participate.",[467],"Heart Diseases",[469,470,471,472,473,474],"Cardiac Surgery","Wound Complication","Rigid Sternal Fixation","Sternal Infection","Pain","Non-union","2026-04-24",{"date":477,"type":34},"2026-04-30",{"date":479,"type":34},"2026-03-12",{"date":481,"type":23},"2027-06-30",{"name":40,"class":41},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":50,"sex":137,"minAge":51,"maxAge":138,"enrollmentInfo":490,"targetDuration":4,"studyType":24,"phases":491,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":501,"leadSponsor":503,"locationsCount":42},"100631359","baby-steps-to-care-100631359","NCT07499648","Baby Steps to Care","Baby Steps to Care - Improving Access to Prenatal Care From the Emergency Department","Inclusion Criteria:\n\n* Found to be pregnant in the CMC Emergency Department through serum or urine pregnancy testing (hcg) or point of care (POC) urine testing\n* Ability to provide verbal consent to this study\n\nExclusion Criteria:\n\n* Prisoners\n* Non-Ohio residents\n* Serious medical conditions (severe cardiovascular disease, infections, trauma) or critical illness requiring urgent hospitalization\n* Nonpregnant persons including men",{"count":208,"type":23},[26],"The purpose of this research study is to understand if receipt of extra prenatal resources from the ED visit improves i) the patient's ability to engage in prenatal services after the ED visit, and ii) how it impacts the patient's pregnancy knowledge and confidence. If participant's consent to this study, the participants will receive standard of care and additionally be randomized, like flipping a coin, to receive either i) extra prenatal care resources in the form of a 'care box' during this ED visit, or ii) the extra prenatal care resources in the form of a 'care box\" two weeks from today. All participants will also receive a follow-up survey asking about the patient's engagement in prenatal services following ED visit, perceptions of pregnancy knowledge and confidence, the usefulness of the resources received, and what additional resources might have been helpful during the early stages of pregnancy. Participation in this study will not require any additional clinic or hospital visits. The total time involved is approximately 20 minutes during the initial ED visit and less than 20 minutes to complete the follow-up survey. Investigators hope to enroll a total of 50 participants in this study.",[494],"Prenatal Follow Up Care",[496],"Emergency Department Visit","2026-04-23",{"date":499,"type":34},"2026-04-28",{"date":497,"type":34},{"date":502,"type":23},"2027-01-01",{"name":40,"class":41},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":24,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":526,"locationsCount":42},"100552474","identification-of-depressive-and-anxiety-symptoms-among-a-sample-of-emergency-department-patients-using-artificial-intelligence-ai-technology-100552474","NCT06473558","Identification of Depressive and Anxiety Symptoms Among a Sample of Emergency Department Patients Using Artificial Intelligence (AI) Technology","Inclusion Criteria:\n\n* Adult patients (age 18 and over) who presents to the UHCMC ED voluntarily with no obvious psychological disturbance by self-report or nurse\u002Fprovider initial assessment\n* English-speaking\n* Patients with non-emergent concerns of Emergency Severity Index (ESI) level 3, 4, or 5\n\nExclusion Criteria:\n\n* Prisoners\n* Patients who are deemed to be critically ill (including life or limb threatening illness) or unable to consent\n* Non-English Speaking",{"count":511,"type":23},30,[26],"Behavioral health problems, such as depression and anxiety, are common yet often are not identified by emergency department doctors and nurses. These mental health conditions can be due to medical issues or can worsen medical problems. One way investigators hope to do a better job of learning about mental health is by training Artificial Intelligence (AI) software to detect anxiety and depression by analyzing facial expression and tone of voice.\n\nParticipants are invited to participate in a study which may help improve emergency department care. An audio and video recording of the participant's responses to some simple, non-psychological questions will be analyzed by a computer to determine whether investigators can assess mood and anxiety by analyzing speech and visual patterns. The audio and video will not be listened to nor watched by study personnel, only analyzed by a computer. The investigator's hope is that it will help others in the future by aiding in the assessment of psychological state. This study is being conducted at CMC ED only.",[515],"Artificial Intelligence (AI)",[517,518,519],"Depression","Anxiety","Emergency Department","2026-04-21",{"date":522,"type":34},"2026-04-27",{"date":251,"type":23},{"date":525,"type":23},"2027-02-28",{"name":40,"class":41},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":24,"phases":537,"briefSummary":538,"conditions":539,"keywords":540,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":42},"100627553","pop-singer-pilot-study-100627553","NCT07450131","POP SINGER Pilot Study","Pain Management Optimized Through Patient-centered Multi-Session Group Music Therapy Within INteGrative sharEd progRamming: A Single-arm Pilot Study","POP SINGER 1","Inclusion Criteria:\n\n* Adults age 18 and older\n* Reporting pain on most days per month for a duration of ≥3 months\n* Independently ambulatory\n* Willing to participate in full scope of program\n* Access to internet, active email address, \\& laptop, tablet, and\u002For PC with videoconferencing capabilities\n* Have reliable access to a mobile device with an active data plan at home and is comfortable accessing the internet and their email with this device\n* Able to read and understand English\n\nExclusion Criteria:\n\n* Significant hearing and\u002For visual impairment\n* Have had a major surgery (e.g., spine surgery, joint replacement) within the past 6 months\n* Have a planned surgery within the next 6 months at the time of enrollment\n* Unable to independently provide consent (i.e., no proxy consent)\n* Active suicidal ideation\n* Severe psychological comorbidity (e.g., psychosis, schizophrenia) that would prevent patient from engaging fully in intervention\n* Receiving active cancer treatment\n* Diagnosed with medical condition likely to be terminal within 24 weeks\n* Active substance abuse diagnosis in EHR\n* Currently receiving music therapy from a professional music therapist",{"count":536,"type":23},24,[26],"Conduct a single-arm pilot study (N = 24) to examine the feasibility and acceptability of the hybrid (i.e., half in-person, half online) POPSINGER group Music Therapy (MT) intervention.",[89],[92,89,541,542],"Group Medical Visits","Virtual","2026-04-17",{"date":520,"type":34},{"date":546,"type":34},"2026-03-13",{"date":548,"type":23},"2026-07-31",{"name":40,"class":41},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":24,"phases":558,"briefSummary":559,"conditions":560,"keywords":563,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":571,"leadSponsor":573,"locationsCount":42},"100595002","using-mindfulness-in-an-enhanced-recovery-after-surgery-protocol-to-support-recovery-after-colorectal-surgery-100595002","NCT07026786","Using Mindfulness in an Enhanced Recovery After Surgery Protocol to Support Recovery After Colorectal Surgery","Using Mindfulness in an Enhanced Recovery After Surgery Protocol to Support Recovery After Colorectal Surgery: A Single Center RCT Feasibility Study","Inclusion Criteria:\n\n* Patients scheduled for a bowel resection and enrolled in the UH Institutional ERAS pathway\n* Patients will be admitted to the inpatient hospital for at least one day postoperatively\n* Aged 18 or older\n* Receiving surgery at designated University Hospitals locations (Cleveland Medical Center, Ahuja, St. John's Medical Center)\n* English-speaking\n* Access to the internet via phone, laptop, or iPad\n\nExclusion Criteria:\n\n* Surgery for palliative purposes only\n* Surgery for ostomy take-down only\n* Discharged on day of surgery\n* History of substance use disorder\n* Allergy or intolerance to all opioids\n* Insufficient English proficiency\n* No access to the internet outside clinical settings\n* Significant visual, hearing or cognitive impairment",{"count":208,"type":23},[26],"This study teaches participants who are having colorectal surgery how to use mindfulness to feel calmer and manage pain better. Participants will be randomized (like a flip of a coin) into one of two groups: Mindfulness Intervention or Standard Treatment. Those in the Mindfulness group will have a 30-minute Zoom session before surgery to learn simple mindfulness exercises like deep breathing, using senses, and staying focused on the present.\n\nOn the day after surgery, participants will watch a short video review of the mindfulness exercises.\n\nRegardless of the group assigned, participants may be asked to complete questionnaires, and some participants will be asked to complete a semi-structured interview via Zoom, about 2 weeks to 1 month after surgery. Additionally, access to the mindfulness curriculum will be provided to those not randomized to that group. Investigators will collect information such as age, surgery details, pain levels, and pain medication usage. Participants will also fill out surveys before and after surgery to assess physical and mental well-being. All personal information will be kept safe, and interviews or Zoom sessions will be deleted after notes are taken without names attached.\n\nParticipants will be in this study for about 4 weeks.",[561,562],"Pain After Surgery","Anxiety After Surgery",[564,565,566],"Colorectal surgery patients","Mindfulness","Enhanced Recovery After Surgery","2026-04-07",{"date":569,"type":34},"2026-04-13",{"date":275,"type":34},{"date":572,"type":23},"2027-09-01",{"name":40,"class":41},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":50,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":580,"targetDuration":582,"studyType":113,"phases":4,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":42},"100454324","human-skin-and-gut-mycobiome-and-bacteriome-comprehensive-registry-100454324","NCT05196061","Human Skin and Gut Mycobiome and Bacteriome Comprehensive Registry","Inclusion Criteria:\n\n* Capable of giving informed consent.\n* Able and willing to complete all required specified study procedures\n\nExclusion Criteria:\n\n* Antibiotic or antifungal use whether topical or systemic in the past 2 or 4 weeks, respectively.\n* Unable and\u002For unwilling to complete all required study procedures.",{"count":581,"type":23},5000,"1 Day","Bacterial and fungal microbiota will be different between individual body sites; however, particular microbiome profiles both whole-body and site-specific will be unique to volunteers with a given parameter such as medical diagnosis, diet, medications taken, geographical area; etc.",[585],"Healthy Volunteers",{"date":569,"type":34},{"date":588,"type":34},"2020-01-01",{"date":590,"type":23},"2030-12-31",{"name":40,"class":41},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":24,"phases":601,"briefSummary":602,"conditions":603,"keywords":606,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":618},"100556289","direct-comparison-of-cardiac-ct-with-tee-to-evaluate-watchman-flx-laa-occluder-device-characteristics-100556289","NCT06523166","Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics","Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics: A Multicenter Study","Inclusion Criteria:\n\n* Subjects \\>18 years old planned to undergo LAAC\n* eGFR ≥ 30 mL\u002Fmin per 1.73 m2\n\nExclusion Criteria:\n\n* Subjects below the age of 18\n* non-English speaking subjects\n* eGFR \\\u003C 30 mL\u002Fmin per 1.73 m2\n* Subjects with history of contrast allergy\n* Pregnant women",{"count":600,"type":23},320,[26],"The current standard of care for patients who underwent left atrial appendage closure (LAAC) is to have follow-up transesophageal echocardiogram (TEE) for device surveillance. TEE is an ultrasound of the heart done by placing a probe in the esophagus under conscious sedation. It does not use contrast but can be cumbersome to patients as it involves placing a probe in the esophagus. Cardiac computerized tomography angiography (cardiac CTA) is a non-invasive imaging modality that involves the use of certain types of x-rays, contrast (dye) and special computers to generate accurate images of the heart. Participants in this study will undergo both TEE and CTA on the same day 90 days after their LAAC procedure.\n\nParticipants will be in this research study for a period of 1 year, starting from the day of their scheduled LAAC procedure. Participants will undergo a TEE at 90 days after their procedure which is the standard of care imaging study after LAAC. As part of this study, participants will also undergo a cardiac CTA at 90 days as well. Participants will have a routine follow-up visit following device placement as per standard of care as well as a brief phone \"check in\" at 1 year.",[604,605],"Device Related Thrombosis","Peri-device Leak",[607,608,609,610],"Watchman FLX","Left atrial appendage (LAA)","Transesophageal echocardiography (TEE)","Cardiac CTA","2026-04-01",{"date":567,"type":34},{"date":614,"type":34},"2026-03-27",{"date":616,"type":23},"2026-08-31",{"name":40,"class":41},5,{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":233,"enrollmentInfo":626,"targetDuration":4,"studyType":24,"phases":628,"briefSummary":629,"conditions":630,"keywords":631,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":640,"locationsCount":42},"100460062","phase-4-development-of-predictive-psoriasis-response-endotypes-using-single-cell-transcriptomics-100460062","NCT05270733","Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics","Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics in Ustekinumab Responders Versus Non-responders","Inclusion Criteria:\n\n* Diagnosed with plaque-type psoriasis defined by either:\n\n  * A board-certified dermatologist, OR\n  * Dermatology Nurse Practitioner, OR\n  * Skin punch biopsy\n* Insurance that includes an anti-p40 biologic (ustekinumab\u002F.Stelara) and at least one anti-p19 biologic (guselkumab\u002FTremfya or risankizumab\u002FSkyrizi)\n* Must be naive to ustekinumab, guselkumab, and risankizumab.\n* Involvement of body surface area (BSA) of at least 10% at screening and baseline visit.\n* Able to give informed consent under IRB approval procedures\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding, or planning to get pregnant 8 weeks before, during, and 8 weeks after the study.\n* Inability to provide informed consent\n* Inability to secure ustekinumab and either gusekumab or risankizumab for use while on trial\n* Use of tanning booths for at least 4 weeks prior to baseline visit\n* Current or recent use of topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 2 weeks prior to baseline visit and for duration of trial\n* Current or recent use of systemic or biologic therapy for at least 8 weeks prior to baseline visit\n* Patients with psoriatic arthritis or other rheumatologic diseases (e.g., Crohn's disease).",{"count":627,"type":23},56,[142],"The investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or reducing the trial-and-error approach often employed. The ability to rule out (or in) specific therapeutics based on predictive efficacy would lead to a more personalized approach for psoriasis treatment.\n\nTo do this, the investigators will be asking participants to try two different already on the market FDA-approved psoriasis drugs for 8 weeks at a time. The investigators will be monitoring participants skin for improvements as well as taking blood and skin samples at least three times. Investigators may also ask to take stool samples and\u002For skin swabs.",[358],[632,365,360,633],"ustekinumab","psoriasis","2026-03-28",{"date":636,"type":34},"2026-04-02",{"date":638,"type":34},"2022-11-10",{"date":162,"type":23},{"name":40,"class":41},{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":648,"targetDuration":4,"studyType":24,"phases":650,"briefSummary":651,"conditions":652,"keywords":653,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":42},"100578219","diagnosis-and-treatment-of-urinary-tract-infection-using-dna-polymerase-chain-reaction-versus-urine-culture-100578219","NCT06808451","Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture","Diagnosis and Treatment of Urinary Tract Infection Using DNA PCR Versus Urine Culture - A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult men and women 18 years and older\n* Presenting to clinic with symptoms of UTI or cystitis\n* Patients with Medicare and Medicaid insurance\n\nExclusion Criteria:\n\n* Urinary diversion of any type\n* Chronic indwelling urinary catheter\n* Diagnosed UTI within the previous 21 days\n* Antibiotic therapy within the previous 21 days\n* Use of phenazopyridine within the previous 21 days\n* Commercial insurance\n* Non-English speaking\n* Pregnant patients",{"count":649,"type":23},136,[26],"Adults 18 years or older with urinary tract infection (UTI) symptoms. Participants will be assigned to either the urine culture group or the DNA PCR study group by randomization. At time of enrollment in the study they will be also asked to fill out two questionnaires. If prescribed antibiotics for treatment of a UTI, participants will then be called the day after they are scheduled to stop their antibiotics. Participants will be asked to fill out questionnaires the day after finishing antibiotics. Participants will be enrolled in the study for a maximum of 21 days.",[269],[654,655],"urine culture","DNA PCR","2026-03-10",{"date":658,"type":34},"2026-03-11",{"date":660,"type":34},"2025-10-22",{"date":662,"type":23},"2026-09-30",{"name":40,"class":41},""]